These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8994759)

  • 21. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
    Matsumura S; Simor AE
    Clin Infect Dis; 1998 Dec; 27(6):1554-6. PubMed ID: 9868693
    [No Abstract]   [Full Text] [Related]  

  • 22. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
    Lamb HM; Figgitt DP; Faulds D
    Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
    Erlandson KM; Sun J; Iwen PC; Rupp ME
    Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience with quinupristin/dalfopristin in treating infections with vancomycin-resistant Enterococcus faecium in children.
    Gray JW; Darbyshire PJ; Beath SV; Kelly D; Mann JR
    Pediatr Infect Dis J; 2000 Mar; 19(3):234-8. PubMed ID: 10749466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinupristin-dalfopristin: an overview.
    Delgado G; Neuhauser MM; Bearden DT; Danziger LH
    Pharmacotherapy; 2000 Dec; 20(12):1469-85. PubMed ID: 11130220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of vancomycin-resistant enterococcus with quinupristin/dalfopristin and high-dose ampicillin.
    Bethea JA; Walko CM; Targos PA
    Ann Pharmacother; 2004 Jun; 38(6):989-91. PubMed ID: 15100393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinupristin/dalfopristin in neonatal Enterococcus faecium meningitis.
    Gransden WR; King A; Marossy D; Rosenthal E
    Arch Dis Child Fetal Neonatal Ed; 1998 May; 78(3):F235-6. PubMed ID: 9713046
    [No Abstract]   [Full Text] [Related]  

  • 28. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
    Johnson AP; Livermore DM
    Lancet; 1999 Dec; 354(9195):2012-3. PubMed ID: 10636359
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quinupristin-dalfopristin.
    Bryson HM; Spencer CM
    Drugs; 1996 Sep; 52(3):406-15. PubMed ID: 8875130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.
    Lynn WA; Clutterbuck E; Want S; Markides V; Lacey S; Rogers TR; Cohen J
    Lancet; 1994 Oct; 344(8928):1025-6. PubMed ID: 7934410
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections.
    Raad I; Hachem R; Hanna H; Afif C; Escalante C; Kantarjian H; Rolston K
    J Antimicrob Chemother; 2004 Apr; 53(4):646-9. PubMed ID: 14998986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
    Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium.
    Smith DL; Johnson JA; Harris AD; Furuno JP; Perencevich EN; Morris JG
    Lancet Infect Dis; 2003 Apr; 3(4):241-9. PubMed ID: 12679267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RP59500 (Quinupristin/dalfopristin): three case reports of its use in infection due to Enterococcus faecium.
    Cassell J; Balakrishnan I; Samarasinghe D; Mistry P; Prentice HG; Gillespie SH
    J Infect; 1998 May; 36(3):324-7. PubMed ID: 9661946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
    Rubinstein E; Bompart F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline.
    Raad I; Hachem R; Hanna H; Girgawy E; Rolston K; Whimbey E; Husni R; Bodey G
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3202-4. PubMed ID: 11600379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
    Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
    J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.